Glycotope GmbH, a leading glycobiology company, has won the innovation award 2010 jointly presented by the German states of Berlin and Brandenburg in recognition of the company's GlycoExpress™ technology platform. GlycoExpress™ combines a very efficient improvement of the activities and side effects of a broad range of protein biopharmaceuticals with the suitability for a much broader patient population and a very high productivity. Currently four therapeutic proteins (3 antibodies) have been produced under GMP two of which are currently tested in clinical trials.
"We are highly delighted", says Dr. Steffen Goletz, CEO, CSO and Founder of Glycotope GmbH. "After receiving the STEP award 2010, winning another prestigious prize within short time is an important recognition of our scientific and corporate advances we have accomplished over the last years".
With close to 70 employees just at the Biotech-campus in Berlin-Buch, Glycotope has developed into an outstanding representative of the Biotech region Berlin-Brandenburg.
Emerging trends in wearable breath sensors aim at personalized healthcare solutions